Abbott Labs (ABT) Stock
Key stats
- Market cap
- $189.28B
- Price / Earnings ratio
- 40.7x
- EPS (TTM)
- $2.69
- Volume
- Loading
- 52-week high
- $132.03
- 52-week low
- $81.97
- Dividend yield
- 2.31%
- Dividend amount (latest)
- $0.63
- EPS vs analyst estimate
- 0.0%Q3 FY25 · $1.30 vs $1.30
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with ABT
Recent news

U.S. politician makes super suspicious Big Tech stock trades
U.S. politician makes super suspicious Big Tech stock trades
ABT

Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks
Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks
ABT

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
ABT

Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?
Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?
ABT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 56.29
- MACD 12/26/9
- 2.23
- EMA 9 of MACD
- 1.82
- MACD histogram
- 0.41
- SMA 50
- $103.98
- Price above SMA 50
- EMA 50
- $105.25
- Price above EMA 50
- SMA 200
- $101.54
- Price above SMA 200
- EMA 200
- $105.75
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 10 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.45 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

U.S. politician makes super suspicious Big Tech stock trades
U.S. politician makes super suspicious Big Tech stock trades
ABT

Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks
Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks
ABT

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
ABT

Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?
Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?
ABT

This Dividend King Just Announced Great News for Investors
This Dividend King Just Announced Great News for Investors
ABT

Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?
Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?
ABT

Abbott's Q3 Earnings Call Focuses on Nutrition Spin-Off and Outlook
Abbott's Q3 Earnings Call Focuses on Nutrition Spin-Off and Outlook
ABT

Cologuard Is Working—So Why Isn't Abbott Stock?
Cologuard Is Working—So Why Isn't Abbott Stock?
ABT

Abbott: 3 Key Takeaways for Long-Term Investors
Abbott: 3 Key Takeaways for Long-Term Investors
ABT

What Abbott Laboratories (ABT) Said on Its Q3 Earnings Call
What Abbott Laboratories (ABT) Said on Its Q3 Earnings Call
ABT
News tone: automated (AI) classification of the article's content, not a price prediction.
About Abbott Labs
Abbott is a global healthcare leader that helps people live more fully at all stages of life. We create breakthrough products – in diagnostics, medical devices, nutrition and branded generic pharmaceuticals – that help you, your family and your community lead healthier lives, full of unlimited possibilities.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert B. Ford | Executive Chairman & CEO | 1974 |
| Mr. Philip P. Boudreau | CFO & Executive VP of Finance | 1973 |
| Mr. Daniel Gesua Sive Salvadori | Executive VP and Group President of Established Pharmaceuticals & Nutritional Products | 1979 |
| Mr. Christopher J. Scoggins | Executive Vice President of Diabetes Care | 1970 |
| Ms. Lisa D. Earnhardt | Executive VP & Group President of Medical Devices | 1970 |
| Ms. Sabina Ewing | Senior VP of Business & Technology Services and Chief Information Officer | 1974 |
| Mr. Michael Comilla | Vice President of Investor Relations. | — |
| Erica L. Battaglia | VP and Chief Ethics & Compliance Officer | — |
| Ms. Elizabeth C. Cushman | Executive VP, General Counsel & Secretary | 1970 |
| Ms. Melissa Brotz | Senior Vice President of Global Marketing & External Affairs | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 56.29
- MACD 12/26/9
- 2.23
- EMA 9 of MACD
- 1.82
- MACD histogram
- 0.41
- SMA 50
- $103.98
- Price above SMA 50
- EMA 50
- $105.25
- Price above EMA 50
- SMA 200
- $101.54
- Price above SMA 200
- EMA 200
- $105.75
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
10 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $118.00
- Average
- $122.80
- High
- $130.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -2.8 | +11.0 | ||||||||||
| 2022 | -8.3 | -5.2 | +0.2 | -4.3 | +4.1 | -5.6 | -1.3 | -6.3 | -7.7 | -0.6 | +8.3 | +1.7 |
| 2023 | +0.9 | -9.0 | +0.4 | +8.7 | -8.2 | +6.0 | +3.8 | -6.9 | -5.8 | -1.2 | +9.8 | +4.9 |
| 2024 | +3.0 | +3.6 | -4.2 | -5.5 | -3.9 | +1.0 | +2.7 | +2.8 | -0.6 | -0.2 | +0.1 | -3.2 |
| 2025 | +12.8 | +7.4 | -5.4 | -0.7 | +2.1 | +1.8 | -7.4 | +4.2 | +1.9 | -7.4 | +4.1 | -2.1 |
| 2026 | -12.0 | +6.3 | -10.0 | -11.3 | -4.3 | +3.4 | +14.7 | +3.0 | -9.3 | +9.8 | +0.3 |



